Saniona is a clinical-stage biopharmaceutical company focused on treatments that act on ion channels, with programs aimed at rare diseases and neurological or psychiatric conditions. Its approach centers on proprietary chemistry and ion-channel biology rather than broad primary-care drugs. Revenue is typically small and milestone- or partnership-driven while candidates advance through research and clinical development.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 9.8 | — | 18.9 | — |
| Q2 2025 | 9.3 | — | -22.2 | — |
| Q3 2025 | 410.7 | — | 329.6 | — |
| Q4 2025 | 4.6 | — | -41.7 | — |
| Q1 2026 | 4.7 | -52.2% | -46.2 | -343.6% |
All markets — KeepWinning global stock screener
Other companies on Stockholm: Siljansvik AB (publ) (SIVI), BioInvent International AB (publ) (BINV), Inission AB (publ) (INISS B), Flerie AB (publ) (FLERIE), BICO Group AB (publ) (BICO), Midsona AB (publ) (MSON B)